GERNHealthcare · BiotechnologyThe 5 Wall Street analysts covering Geron Corp. hold a median 12-month price target of $4 — +172.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 52 of 100 as at 15 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Geron Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (89): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Accruals (25): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on GERN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +172.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 5 Nov 2025 | Needham | Maintains | Buy | $5.00 → $4.00 |
| 5 Nov 2025 | Needham | Maintains | Buy | — |
| 10 July 2025 | Goldman Sachs | Reinstates | Sell | $1.00 |
| 8 May 2025 | Scotiabank | Downgrade | Sector Perform | — |
| 12 Mar 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 12 Mar 2025 | Needham | Reiterates | Buy | — |
| 27 Feb 2025 | Barclays | Maintains | Overweight | — |
| 27 Feb 2025 | Needham | Maintains | Buy | — |
| 27 Feb 2025 | Scotiabank | Maintains | Sector Outperform | — |
| 27 Feb 2025 | Stifel | Maintains | Buy | — |
| 26 Feb 2025 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 18 Feb 2025 | B. Riley Securities | Maintains | Buy | — |
| 13 Jan 2025 | Needham | Maintains | Buy | — |
| 13 Dec 2024 | Needham | Reiterates | Buy | — |
| 10 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 Nov 2024 | HC Wainwright & Co. | Initiates | Buy | — |
| 16 Oct 2024 | Scotiabank | Initiates | Sector Outperform | — |
| 9 Sept 2024 | Leerink Partners | Initiates | Outperform | — |
| 9 Aug 2024 | Needham | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GERN appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 93% of US stocks
Cheaper than 28% of US stocks
Cheaper than 27% of US stocks
Cheaper than 89% of US stocks
Higher than 66% of US stocks
Higher than 56% of US stocks
Higher than 93% of US stocks
Higher than 21% of US stocks
Higher than 13% of US stocks
Higher than 27% of US stocks
Higher than 33% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Geron Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seeking Alpha has published the transcript of Geron Corporation's Q2 2026 earnings call. The item signals the availability of the full management discussion from the company's quarterly earnings report.
Why it matters — GERN watchers can review the earnings call transcript for management's discussion of the company's latest quarterly business and financial performance.
Geron reported a Q2 loss of $0.02 per share, matching the year-ago loss but missing the Zacks Consensus Estimate of a $0.01 loss. Revenue for the quarter exceeded analyst expectations.
Why it matters — The revenue beat and in-line loss per share offer a checkpoint on Geron's financial performance against analyst expectations ahead of potential catalysts for its lead drug candidate.
Geron reported second-quarter net revenue of $57.5 million, up 17% year over year and 11% sequentially, as the company continued to expand use of RYTELO in patients with lower-risk myelodysplastic syndromes (MDS).
Why it matters — The 17% year-over-year and 11% sequential revenue growth signals continued momentum for RYTELO adoption in the lower-risk MDS market.
Geron Corporation reported second quarter 2026 financial results, with RYTELO net product revenue reaching $57.5 million, an 11% increase from the prior quarter. The company reiterated its full-year 2026 revenue guidance of $220-$240 million and total operating expense guidance of $230-$240 million.
Why it matters — GERN watchers would care because the quarterly revenue update and reiterated full-year guidance provide a snapshot of RYTELO's commercial trajectory and the company's financial outlook.
The 5 Wall Street analysts covering Geron Corp. have a median 12-month price target of $4, with estimates ranging from $3 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering Geron Corp., 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Geron Corp. 52 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 15 Aug 2026, Geron Corp. ranks 52 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (89 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +172.1% from the last close, and Ticker Nerd's factor model ranks Geron Corp. 52 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Geron Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GERN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $6 over the next 12 months.
Geron Corp. returned +1.4% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Geron Corporation is a commercial-stage biopharmaceutical company focused on blood cancers and myeloid hematologic malignancies through telomerase inhibition. The company's primary product is RYTELO (imetelstat), a first-in-class telomerase inhibitor approved in the United States and the European Union for adult patients with lower-risk myelodysplastic syndromes who have transfusion-dependent anemia.
The most recent item we track (Seeking Alpha, 5 Aug 2026): "Geron Corporation (GERN) Q2 2026 Earnings Call Transcript". Seeking Alpha has published the transcript of Geron Corporation's Q2 2026 earnings call. The item signals the availability of the full management discussion from the company's quarterly earnings report.
Geron Corporation is a commercial-stage biopharmaceutical company focused on blood cancers and myeloid hematologic malignancies through telomerase inhibition. The company's primary product is RYTELO (imetelstat), a first-in-class telomerase inhibitor approved in the United States and the European Union for adult patients with lower-risk myelodysplastic syndromes who have transfusion-dependent anemia. RYTELO demonstrated strong commercial momentum, with net product revenue growing substantially as the company expanded its U.S. commercial efforts and clinical development programs. Geron is also advancing the Phase 3 IMpactMF trial to explore potential label expansion in myelofibrosis, alongside investigator-sponsored and real-world evidence studies. The company pursues a focused strategy on hematology-oncology, leveraging telomerase inhibition as a mechanism to address blood cancers. Founded in 1990 and headquartered in Foster City, California, Geron operates as a single-segment organization dedicated to bringing innovative therapeutic options to patients with serious blood disorders and malignancies.
CEO Mr. Harout Semerjian · 258 employees · United States · https://www.geron.com